Pfizer Inc. (NYSE:PFE) Shares Sold by Pathway Financial Advisers LLC

Pathway Financial Advisers LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 1.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,587 shares of the biopharmaceutical company’s stock after selling 1,091 shares during the period. Pathway Financial Advisers LLC’s holdings in Pfizer were worth $1,609,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. LGT Group Foundation grew its position in shares of Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after acquiring an additional 18,274 shares during the last quarter. ORG Partners LLC raised its holdings in shares of Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 44,458 shares during the last quarter. Kempner Capital Management Inc. acquired a new stake in shares of Pfizer during the first quarter worth about $2,439,000. Leo Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter worth about $2,171,000. Finally, Power Corp of Canada lifted its position in Pfizer by 28.1% during the 4th quarter. Power Corp of Canada now owns 174,201 shares of the biopharmaceutical company’s stock worth $5,015,000 after acquiring an additional 38,243 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.5 %

Shares of NYSE:PFE opened at $28.94 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market cap of $163.96 billion, a price-to-earnings ratio of -482.25, a PEG ratio of 1.27 and a beta of 0.68. The stock’s 50-day moving average price is $29.29 and its two-hundred day moving average price is $28.30. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.11.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.